Drugmaker patient assistance rules for 31 drugs at 13 drugmakers, each read on the drugmaker's own page on 2026-10-29: stated one-person income limits run from $31,920 to $79,800; Ozempic shows no figure, Wegovy is not listed, Farxiga was removed for new patients.
Download the file or read the study for its structure; both are linked above.
Released under CC BY 4.0. You may use it commercially and redistribute it. Attribution is the only condition.
Couey, V. W. (2026). Patient Assistance Program Eligibility by Drug 2026: What Each Drugmaker Publishes, Read on the Sponsor's Own Page. Deep Synthesis. https://doi.org/10.5281/zenodo.23812709
Found an error, need a different cut of this data, or citing it in something? vincent@deepsynthesis.org. Corrections are made against the published file and the DOI is versioned, so a fix is traceable rather than silent.
FDA CAERS-derived adverse event reports for dietary supplements over a decade: ingredient category, severity, outcome, year. Modeled estimates.
Pharmacy benefit manager spread economics: NADAC reference price vs reimbursed price vs plan-paid price across high-volume generics.
Brand-name drug patent expirations 2024-2028, generic entry timing, and per-drug savings on substitution.